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Verteporfin (VP), a light-activated drug used in photodynamic therapy for the treatment of choroidal 
neovascular membranes, has also been shown to be an effective inhibitor of malignant cells. Recently, 
studies have demonstrated that, even without photo-activation, VP may still inhibit certain tumor cell 
lines, including ovarian cancer, hepatocarcinoma and retinoblastoma, through the inhibition of the YAP-
TEAD complex. In this study, we examined the effects of VP without light activation on human glioma 
cell lines (LN229 and SNB19). Through western blot analysis, we identified that human glioma cells that 
were exposed to VP without light activation demonstrated a downregulation of YAP-TEAD-associated 
downstream signaling molecules, including c-myc, axl, CTGF, cyr61 and survivin and upregulation of the 
tumor growth inhibitor molecule p38 MAPK. In addition, we observed that expression of VEGFA and the 
pluripotent marker Oct-4 were also decreased. Verteporfin did not alter the Akt survival pathway or the 
mTor pathway but there was a modest increase in LC3-IIB, a marker of autophagosome biogenesis. This 
study suggests that verteporfin should be further explored as an adjuvant therapy for the treatment of 
glioblastoma.
Gliomas are the most common primary brain tumors1, 2. Histopathologically, they are classified by the World 
Health Organization (WHO) as astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and ependymoma 
with glioblastoma (WHO astrocytoma grade IV) being the most common adult glioma1, 2. In the eye, optic nerve 
gliomas (ONGs) comprise 2–5% of all pediatric central nervous system (CNS) tumors and are the most common 
CNS tumors in patients with neurofibromatosis type 1 (NF1)3.
Signs and symptoms of gliomas depend on the site of CNS that is affected. For instance, brain gliomas cause 
headache, vomiting, and seizures1, while the presenting clinical signs of ONGs include mild to profound vision 
loss, proptosis, optic disk swelling or pallor, ophthalmoplegia, and strabismus4–8. Gliomas are rarely curable and the 
prognosis of patients with high grade gliomas is usually poor1, 2. Neither surgery, chemotherapy, nor radiation has 
been demonstrated to prolong survival in cases of malignant optic nerve glioma4–8. Moreover, even in cases of low 
grade glioma in children, treatment is associated with significant morbidity, with risks including iatrogenic damage 
to the optic nerve, cortical atrophy, degenerative vascular changes and increased incidence of secondary tumors9.
A recent experimental innovation in cancer therapy has been the use of porphyrins, which are organic het-
erocyclic molecules consisting of four modified pyrrole units interconnected via methane bridges10. A unique 
feature of porphyrins is their ability to act as photosensitizers10. One clinical application of porphyrins in the 
eye is through photodynamic therapy (PDT), a Food and Drug Administration (FDA)-approved intervention to 
treat discrete subfoveal choroidal neovascular membranes secondary to age related macular degeneration11. PDT 
involves intravenously administering verteporfin (trade name Visudyne), which accumulates in neovascular sub-
retinal vessels, and is then activated upon exposure to 693 nm, low-energy, nonthermal infrared laser. Activation 
of verteporfin (VP) produces free radicals in the abnormal vessels resulting in their destruction through mul-
tiple mechanisms including a direct cytotoxic effect, promotion of vascular thrombosis, as well as an immune 
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mediated effect. The highly localized effect spares the overlying fovea and retinal pigment epithelium. Since its 
first application, its use has expanded worldwide and has preserved vision in tens of thousands of patients12.
More recently, PDT has also been experimentally used as a light-based therapeutic modality for several human 
malignancies13–17. It has been proposed that the therapeutic mechanism of treating malignancies with VP is not 
only through its light-activated destruction of neovascular vessels, but also as a possible inducer of apoptosis or 
autophagy in malignant cells18.
Yes Associated Protein (YAP), a candidate oncogene on the human chromosome 11q22 amplicon, and com-
ponent of the Hippo-pathway has been associated with human tumorigenesis19–21. In addition, high YAP nuclear 
levels are present22–24 and have been linked to chemoresistance25–28 in various cancer types. YAP works as a tran-
scriptional coactivator and binds to several DNA-binding transcription factors; the best characterized have been 
the TEAD family of transcription factors29. Recent studies have shown that VP may disrupt the YAP-TEAD com-
plex and inhibit growth of hepatocellular carcinoma and ovarian cancer without light activation10, 30. In addition, 
we recently demonstrated verteporfin’s ability to interfere with the YAP-TEAD signaling pathway, resulting in a 
downregulation of proto-oncogenes, molecules involved in angionesesis and cell migration, and a reduction in the 
pluripotency cell marker Oct-431. Drugs that disrupt YAP-TEAD interaction can have selective effects on malig-
nant cells with minimal toxicity on the surrounding healthy tissues because this pathway is usually not active in 
normal tissues. This makes these drugs an attractive potential novel therapeutic option. Given the recently char-
acterized role of YAP expression in human glioblastoma32, 33 and the need to identify less toxic and more effective 
therapies for this deadly cancer, we investigated the effects of non-light activated VP on human glioma cells.
Materials and Methods
Reagents. Verteporfin (Visudyne) was obtained from Novartis (Novartis, Basel, Switzerland) and MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was purchased from Sigma Aldrich (St.Louis, 
MO, USA). The following primary antibodies were purchased from Cell Signaling Technology (Danvers, MA, 
USA) and were diluted 1:1000 unless stated otherwise: c-myc, axl, phospho-S6 ribosomal protein (Ser235/236), 
phospho-4EBP1 (Thr37/46), LC3B, phospho-p38 MAPK (Thr180/Tyr182), 4-Oct, survivin, pAkt (S473) (1:2000). 
The following antibodies were purchased from Santa Cruz Biotechnology (Dallas, Texas, USA): cyr61 (1:500), 
VEGFA (1:500), CTGF (1:500).
Cell culture. Human glioma cell lines LN229 and SNB19 were purchased from Leibniz Institute DSMZ 
German Collection of Microorganisms and Cell Lines (Leibniz, Germany) and were grown in DMEM medium 
(Invitrogen, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (ATCC), penicillin 
(100 μg/ml), streptomycin (100 μg/ml), 10 mM HEPES (all obtained from Invitrogen). Cells were incubated at 
37 °C in a humidified atmosphere of 95% air and 5% CO2 and split when the cells reached approximately 80% 
confluence. Cells were continuously protected from light (by the use of aluminum foil) and all experiments were 
performed in darkness.
Assessment of growth curves. The cells were seeded in 6-well plates with approximately 100 000 cells per 
well. One day later, verteporfin was added (final concentrations 2 µg/ml or 10 µg/ml) and cells were incubated for 
3 and 6 days. At days 2, 4 and 6, cell number and viability were determined by the trypan blue (0.4%) dye exclu-
sion method. Growth curves were drawn.
Measurement of cell growth and viability by the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium Bromide) assay. Cell viability was assessed by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. The MTT assay is used to measure the reduction of a tetrazolium 
compound by the cellular mitochondria, which produces the optically active compound formazan.
Cells were cultured in 96-well plates at an amount of 10 000 cells per well. After 3 and 6 days of treatment with 
VP, MTT (5 mg/mL in PBS) was added to each well at a 1/10 volume. Cells were incubated for 1 hour at 37 °C and 
resuspended in DMSO. The absorbance at 595 nm was measured using a microplate reader. Data are displayed as 
percentage of control.
Protein extraction and western blot analysis. Cells were incubated for 24 hours in the presence of VP 
at concentrations of 2 µg/ml and 10 µg/ml. Control cells were treated with PBS. The samples were lysed in M-PER 
Mammalian Protein Extraction Reagent (Thermo-Scientific, Rockford, IL USA) supplemented with protease (as 
per manufacturer recommendation; Roche Applied Science) and phosphatase inhibitor cocktails (dilution 1:50; 
Thermo-Scientific, Pierce Protein Research Products). All cells and samples were continuously protected from light. 
Ten micrograms of total protein were loaded onto 4–12% Bis-Tris Gel (NuPAGE; Invitrogen). Electrophoresis was 
performed in darkness using NuPAGE MOPS Running Buffer (Invitrogen) and then samples were transferred onto 
a PVDF membrane (Millipore, Billerica, MA, USA). After transfer, the membranes were stained with Coomassie 
blue to ensure equal loading, and then blocked for 45 minutes at room temperature in 5% wt/vol BSA followed by 
incubation overnight at 4 °C with the above listed rabbit anti-human primary antibodies. Then the membranes 
were washed three times with 1xTBS 0.1% Tween 20 and incubated for 45 minutes at room temperature with the 
horseradish peroxidase-labeled secondary anti-rabbit antibody at 1:50000 (Jackson ImmunoResearch, West Grove, 
PA, USA). The immunoreactive bands were visualized with ECL exposure onto Fuji RX film (Fujifilm,Tokyo, 
Japan). The results were quantified using ImageJ software (National Institutes of Health, Bethesda, MD; available at 
http://imagej.nih.gov/ij/) relative to Coomassie blue staining as a loading control.
Statistical analysis. Data are expressed as mean and standard error of the mean (SEM). Statistical signifi-
cance was evaluated using the one-way ANOVA test with Dunnett’s modification for multiple means comparison 
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or a t-test for two mean comparisons. A p value of < 0.05 was considered to be significant. Two-tailed tests were 
used for all comparisons.
Results
Verteporfin inhibits cell growth and viability of human glioma cell lines. To determine if VP inhib-
its human glioma cell growth and proliferation without light activation, we analyzed its effect on the growth of 
human glioma cell lines LN229 and SNB19. The cell lines were exposed to one of three arms: VP 2 µg/ml, VP 
10 µg/ml, or a placebo group with a vehicle control. Cells were continuously protected from light. Both vertepor-
fin exposed cell lines demonstrated dose-dependent decrease in cell growth as measured by trypan blue exclusion 
testing (Fig. 1A,B). Similarly, a statistically significant inhibition of cell growth and viability was observed in 
verteporfin treated cells using the MTT assay (Fig. 1C,D).
VP affects YAP-TEAD signaling pathway in human glioma cells. We next examined whether cells 
exposed to VP had a change in the expression of genes regulated by TEAD. At 24 hours, cells treated with VP 
(2 µg/ml and 10 µg/ml) demonstrated a dose-dependent downregulation of pro-proliferative molecules that are 
affected by a YAP-TEAD interaction, including c-myc, axl, survivin, cyr-61 and CTGF (Fig. 2A–E).
VP down-regulates VEGFA expression and pluripotency marker Oct-4 in human glioma 
cells. It has been previously shown that TEAD is involved in VEGF, a key mediator of angiogenesis in cancer, 
expression via interaction with Vestigial-like (Vgll) transcription coactivators34. We demonstrated using west-
ern blot analyses that a dose-dependent decrease of VEGFA-expression was observed in glioma cells that were 
exposed to VP (Fig. 3A). OCT-4, a pluripotency cell marker that is expressed in cancer cells including cancer stem 
cell subpopulations, has been shown to be highly expressed in human gliomas and this expression increases in 
parallel with increasing glioma grades35. The YAP-TEAD pathway has also been shown to interact with OCT-436. 
Our finding that VP causes a downstream decrease in YAP-TEAD pathway associated molecules prompted us to 
test the effect of VP on OCT-4 in glioma cells. Our results show that exposure of the glioma cells to VP is associ-
ated with a reduction in OCT 4 (Fig. 3B).
VP activates p38 MAPK in human glioma cells. A major regulator of the cell cycle and apoptosis are 
mitogen-activated protein kinases (MAPKs)17, and p38 MAPK activation is associated with an inhibition of 
tumor growth. In our study, exposure of glioblastoma cells to VP was also associated with induced expression of 
p38 MAPK (Fig. 4).
Figure 1. Verteporfin (VP) inhibits growth of glioblastoma LN229 and SNB19 without light activation. 
Glioblastoma cell lines (SNB19 and LN229) were treated with vehicle (PBS), 2 µg/ml VP or 10 µg/ml of VP 
for 2,4, and 6 days (A,B) or 3 and 6 days (C,D) protected from light at all steps. (A,B) Cell growth curves as 
determined by trypan blue exclusion counting. VP treatment resulted in a dose-dependent inhibition of cell 
growth. (N = 3, error bars are SE, *p < 0.5 (C,D) Cell viability assessed by MTT assay. Results expressed as 
percentage of growth (%) relative to control values. (N = 3, error bars are SE, ***p < 0.001, *p < 0.5).
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VP does not affect the mTOR pathway while it slightly increases LC3-IIB protein levels in 
human glioma cells. Recently it was determined that YAP mediates crosstalk between the Hippo and PI(3)
K–mTOR pathways and activates the mammalian target of rapamycin (mTOR), which is a major regulator of cell 
growth19. Western blots of whole cell lysates showed that VP treatment does not affect the phosphorylation status 
of ribosomal S6, p4EBP1 protein (Fig. 5A,B), or Akt Ser 473 (Fig. 5C). VP treatment led to a small increase in 
LC3-IIB protein levels in glioblastoma cells (Fig. 5D).
Discussion
Despite the recent advances, malignant glioma remains a disease that results in death within a short period of 
time. In addition, in the pediatric population, treatment of benign glioma is associated with significant morbidity, 
underscoring the need for new targets and less toxic therapies. In this study, we demonstrate that human glioblas-
toma cell growth is inhibited in vitro when exposed to VP without the presence of light activation. VP may have 
a direct inhibitory effect on retinoblastoma, hepatocarcinoma, and ovarian cancer cells growth via disruption of 
the YAP-TEAD complex and the prevention of YAP-induced oncogenic growth10, 30, 31. YAP has been identified 
as a transcription coactivator that binds several transcription factors, including TEAD that is crucial for cellular 
development and cancer progression29. TEAD can also interact with multiple other coactivators that play an 
important role in cancer progression, such as Vgll proteins that upregulate the expression of VEGFA gene, the 
pro-angiogenic factor involved in cancer pathogenesis34. TEADs and their coactivators facilitate the progression 
of many cancers, including glioblastoma, through the upregulation of genes mediated by YAP, including c-myc, 
survivin, Axl, CTGF and Cyr6137, 38. The function of these genes is to promote cellular proliferation, tumor cell 
invasion, inhibition of apoptosis, metastasis, and epithelial-mesenchymal transition39–42. In our study VP treat-
ment was associated with downregulation of these procancer proteins as well as downregulation of the proangi-
ogenic protein VEGF.
In addition to VP’s effects on pathways that promote cancer growth, treatment of glioblastoma cells with 
VP was also associated with an increased expression of LC3IIB, a marker of autophagosome biogenesis. 
Accumulation of autophagosome may represent either autophagy induction or, alternatively, suppression of the 
autophagy pathway downstream of autophagosome formation43. In fact, Donohue E et al. showed that VP is a late 
stage autophagy inhibitor in MCF-7 cells44. Autophagy, the process of degrading unnecessary cellular proteins 
Figure 2. Verteporfin (VP) downregulates several members of the YAP-TEAD effectors in glioblastoma cells. 
SNB19 and LN229 cells were treated with vehicle (C), 2 µg/ml of VP (L) or 10 µg/ml of VP (H) for 24 hours 
protected from light at all steps. Western blot of protein extracts were probed for (A) c-myc, (B) axl, (C) 
survivin, (D) cyr-61, and (E) CTGF. Cropped blots are shown. Quantification of the blots relative to Coomassie 
blue staining, as a loading control, is on the right. (Experiment repeated 3 times, representative blot is shown 
here).
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and organelles through the actions of lysosomes, can be an appropriate response to stress and promote survival, 
but persistent stress can lead to autophagic (or programmed type II) cell death45. Therefore, the increased expres-
sion of LC3IIB suggests that verteporfin may affect cancer autophagic cell death, but this effect could be different 
among different cancer types and different experimental conditions. VP has been shown to induce, in a non-light 
dependent mechanism, the formation of cross-linked oligomers and high molecular weight protein complexes 
(HMWC) that could interfere with autophagy and cancer cell growth46, 47. More recently, our group showed that 
the prevalence of at least some HMWCs is likely due to the presence of ambient light during post-lysis analysis48. 
Our data in the current study suggests that the observed downregulation of some YAP-TEAD-associated down-
stream signaling molecules in darkness is not due to HMWC formation (Supplementary Figures 1 and 2) and that 
VP may have direct effects on some cancer growth pathways.
An anti-proliferative effect of verteporfin on human glioblastoma cells was also observed through activation 
of p38 MAPK, which has been implicated in the inhibition of tumor growth49. Activation of p38 MAPK induces 
apoptosis in multiple cancer cell lines, including acute lymphoblastic leukemia and hepatoma cells50, and also 
promotes the mitochondrial apoptotic pathway51. We therefore suggest that p38 may mediate VP’s effect on glio-
blastoma cells. Interestingly, VP treatment of human glioblastoma cells did not affect Akt or mTOR pathway, 
which is in contrast to our prior results on the effect of VP on human retinoblastoma31. This is a surprising finding 
because YAP mediates crosstalk between the Hippo and phosphatidylinositol 3-kinase (PI3K)/AKT signaling 
Figure 3. Verteporfin (VP) inhibits expressions of VEGFA and OCT-4 in glioblastoma cells. SNB19 and LN229 
cells were treated with vehicle (C), 2 µg/ml of VP (L) or 10 µg/ml of VP (H) for 24 hours protected from light 
at all steps. Western blot of protein extracts were probed for (A) VEGFA, (B) pluripotency marker OCT-4. 
Cropped blots are shown. Quantification of the blots relative to Coomassie blue staining, as a loading control, is 
on the right. (Experiment repeated 3 times, representative blot is shown here).
Figure 4. Verteporfin (VP) activates p38 MAPK glioblastoma cells. SNB19 and LN229 cells were treated with 
vehicle (C), 2 µg/ml of VP (L) or 10 µg/ml of VP (H) for 24 hours protected from light at all steps. Western blot 
of protein extracts showed that VP treatment induced phosphorylation of p38 MAPK in a dose-dependent 
manner. Cropped blots are shown. Quantification of the blots relative to Coomassie blue staining, as a loading 
control, is on the right. (Experiment repeated 3 times, representative blot is shown here).
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pathways and it activates the mammalian target of rapamycin (mTOR), signaling pathways that are important for 
the promotion of tumor proliferation, migration, and apoptosis40–42, 49.
Additionally in this study we found that verteporfin downregulated the pluripotent marker Oct-4, a transcrip-
tion factor that is expressed in cancer stem cells and in human glioma cells35. This builds on our prior work that 
suggests that targeting OCT-4 may beneficial in treating some cancers and supports suggested role of YAP/TEAD 
signaling pathway in pluripotency31.
In summary, we demonstrate for the first time that verteporfin can inhibit growth and proliferation of human 
glioma cells without any light activation in vitro and that this inhibition of cell growth correlates with downreg-
ulation of some YAP/TEAD-associated downstream signaling molecules. It also shows for the second time that 
Verteporfin may interfere with pluripotency marker OCT-4. Our study supports the role of VP as a potential ther-
apy for multiple solid tumors, such as retinoblastoma, hepatocarcinoma, ovarian cancer, and glioma. Further stud-
ies are needed to elucidate the exact mechanism of VP action and supports further exploration in animal research.
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